Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of
            <i>Propionibacterium</i>
            spp., Including 117
            <i>P. acnes</i>
            Isolates

Goldstein, Ellie J. C.; Citron, Diane M.; Merriam, C. Vreni; Warren, Yumi A.; Tyrrell, Kerin L.; Fernandez, Helen T.

doi:10.1128/aac.50.1.379-381.2006

Cited by 33 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies documented the in vitro activities of retapamulin against a variety of clinical species including the predominant pathogens associated with impetigo and other skin and soft tissue infections (12,14,19,20). Data presented here are in agreement with data reported in previously published studies.…”

supporting

confidence: 83%

Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent

Traczewski

Brown

2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Retapamulin, the first pleuromutilin antimicrobial agent approved for the topical treatment of skin infections in humans, was tested against 987 clinical isolates representing 30 species and/or resistance groups. MICs were determined along with disk diffusion zone diameters using a 2-g disk. Population distribution and MIC versus disk zone diameter scattergrams were analyzed to determine microbiological MIC cutoff values and inhibition zone correlates. Minimum bactericidal concentrations were performed on a smaller subset of key species. The retapamulin MIC 90 against 234 Staphylococcus aureus isolates and 110 coagulase-negative staphylococci was 0.12 g/ml. Retapamulin MIC 90 s ranged from 0.03 to 0.06 g/ml against beta-hemolytic streptococci including 102 Streptococcus pyogenes, 103 Streptococcus agalactiae, 59 group C Streptococcus, and 71 group G Streptococcus isolates. The MIC 90 against 55 viridans group streptococci was 0.25 g/ml. Retapamulin had very little activity against 151 gramnegative bacilli and most of the Enterococcus species tested. Based on the data from this study, for staphylococci, MICs of <0.5, 1, and >2 g/ml with corresponding disk diffusion values of >20 mm, 17 to 19 mm, and <16 mm can be proposed for susceptible, intermediate, and resistant microbiological cutoffs, respectively. For beta-hemolytic streptococci, a susceptible-only MIC of <0.25 g/ml with a corresponding disk diffusion value of >15 mm can be proposed for susceptible-only microbiological cutoffs.

show abstract

supporting

confidence: 83%

Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent

Traczewski

Brown

2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The bowel mucosa is inhabited by different Propionibacterium species, and Propionibacterium acnes and other Propionibacterium spp are part of the normal flora of the skin, nasopharynx, oral cavity, and genitourinary tract 7 Although usually nonpathogenic for humans, different documented cases of infection (e.g. in association with implanted prostheses or central nervous system shunts) have been reported 7 14.…”

Section: Discussionmentioning

confidence: 99%

“…Propionibacterium acnes has also been identified as a frequently recovered cause of anaerobic arthritis in association with prosthetic joints, vascular disease, and peripheral neuropathy. Isolation of these microorganisms from patients with osteomyelitis has been reported 7 . In the present case, it was difficult to decide whether the cultured Propionibacterium species were pathogens, since no defined diagnostic criteria are available.…”

Section: Discussionmentioning

confidence: 99%

Mycetoma fungal infection: multiple organisms as colonizers or pathogens?

Pilsczek

Augenbraun

2007

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

We describe a patient with mycetoma or Madura foot, in RESUMO Descrevemos um paciente com micetoma ou maduromicose de pé, no que colorações histopatológicos de osso e de culturas superficiais sugeriram três organismos diferentes, incluindo espécies de Nocardia como causador. Os critérios de diagnóstico dos organismos, a diferenciação entre colonizador e patógeno, e a significância das infecções mistas são discutidos.Palavras-chaves: Micetoma. Maduromicose de pé. Colonização.

show abstract

“…Retapamulin demonstrated favorable in vitro activity against anaerobes, including Propionibacterium species associated with acnes vulgaris, Fusobacterium species, and other anaerobic Gram-positive cocci, 14,17,24 and respiratory tract pathogens, including Haemophilus infl uenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. 16 The in vitro activities of retapamulin against common pathogens associated with uncomplicated SSSIs reported in published studies correspond well with those found in the global surveillance program.…”

Section: In Vitro Activity Of Retapamulin: Published Studiesmentioning

confidence: 99%

“…13 A recent addition to available topical antibiotics is retapamulin, a novel semisynthetic pleuromutilin antibiotic that has a unique mode of action and potent in vitro activity against a wide range of pathogens, particularly Gram-positive cocci. [14][15][16][17] An ointment formulation of 1% retapamulin received regulatory approval from the US Food and Drug Administration for the treatment of impetigo and from the European Medicines Agency in 2007 for the short-term treatment of the following superfi cial skin infections: impetigo and infected small lacerations, abrasions, and sutured wounds. Retapamulin is the fi rst new prescription topical antibiotic in more than 20 years.…”

mentioning

confidence: 99%

Topical retapamulin in the management of infected traumatic skin lesions

Shawar

Scangarella-Oman

Dalessandro³

et al. 2008

TCRM

View full text Add to dashboard Cite

Abstract:Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifi cally designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specifi c crossresistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options.

show abstract

Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of Propionibacterium spp., Including 117 P. acnes Isolates

Cited by 33 publications

References 10 publications

Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent

Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent

Mycetoma fungal infection: multiple organisms as colonizers or pathogens?

Topical retapamulin in the management of infected traumatic skin lesions

Contact Info

Product

Resources

About